查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1856965

全球幹細胞庫市場：預測至2032年－依來源類型、庫類型、服務類型、用途、最終用戶和地區進行分析

Stem Cell Banking Market Forecasts to 2032 - Global Analysis By Source Type (Umbilical Cord Stem Cells, Cord Blood, Cord Tissue, Placenta, Adult Stem Cells and Other Source Types), Bank Type, Service Type, Utilization, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格
幹細胞庫市場預測至2032年－按來源類型、庫類型、服務類型、使用率、最終用戶和地理分類的全球分析

根據 Stratistics MRC 的數據，預計到 2025 年，全球幹細胞庫市場規模將達到 112 億美元，到 2032 年將達到 222 億美元，預測期內複合年成長率為 10.2%。

幹細胞庫是指收集、處理和保存幹細胞，以備將來潛在的醫療用途。這些細胞通常來自臍帶血、骨髓或脂肪組織等，具有分化成多種細胞類型和再生受損組織的獨特能力。儲存的幹細胞可用於再生醫學、器官移植以及治療包括白血病、淋巴瘤和免疫系統疾病在內的多種疾病。幹細胞庫在低溫下儲存，為個人和家庭提供寶貴的生物資源，確保他們未來能夠獲得個人化治療和先進的醫療服務。

根據國際幹細胞研究協會（ISSCR）的數據，全球整體有超過7000項正在進行的幹細胞臨床試驗，這反映了再生醫學的快速研究和發展以及對品質有保證的幹細胞儲存日益成長的需求。

公眾意識的提高和家長需求的增加

越來越多的家庭選擇儲存臍帶血和組織，以備將來用於再生醫學。教育宣傳活動和產前諮詢正在加深人們對幹細胞在遺傳和免疫疾病治療中應用的了解。醫院和婦產中心正與私人臍帶血庫合作，提供臍帶血採集和儲存服務。都市區和半都市區產科服務的可近性和需求的提高正在推動相關業務的成長。這些動態共同推動了預防醫學和個人化醫療市場的擴張。

有限的已證實適應症

幹細胞在治療血液癌症和代謝紊亂方面展現出潛力，但其大部分應用仍處於實驗階段或僅限於臨床試驗。監管機構要求在核准新的治療用途前進行嚴格的檢驗。由於缺乏長期獲益的明確證據，父母可能不願意投資幹細胞庫。新適應症缺乏標準化通訊協定也阻礙了幹細胞療法融入主流醫療體系。這些限制因素阻礙了幹細胞療法更廣泛的應用和醫療保險報銷。

醫療支出和私人投資增加

各國政府正資助生物樣本庫計畫和官民合作關係，以支持再生醫學的發展。創業投資和機構投資者正在扶持專注於整合冷凍保存、分析和細胞療法的新興企業。生育診所和婦產科醫院的擴張正在創造新的樣本採集點和轉診網路。腫瘤學、神經病學和罕見疾病領域對長期生物儲存的需求日益成長。這些趨勢正在推動幹細胞庫生態系統實現可擴展且多元化的成長。

資料隱私、同意和道德透明度問題

各機構必須確保安全處理與儲存樣本相關的遺傳和個人資訊。知情同意通訊協定必須清楚、符合年齡要求，並符合各司法管轄區的法律規定。關於樣本商業化、捐贈者權利和未來用途的倫理問題需要強而有力的管治。跨境儲存和合作研究正受到日益嚴格的監管審查。這些風險持續限制平台的信譽和相關人員的參與。

新冠疫情的影響：

疫情擾亂了產科護理和擇期手術，導致幹細胞採集量暫時下降。然而，疫情後的復甦重點在於將預防性護理和生物銀行建設作為長期韌性的一部分。醫院已恢復臍帶血採集，並透過與私人血庫合作擴大了獲取途徑。疫情期間，民眾對免疫健康和再生療法的關注度有所提高。對數位化知情同意、遠端諮詢和物流的投入提高了營運的連續性。這些變化正在加速幹細胞庫建設與兒童保健的長期融合。

預計在預測期內，臍帶血幹細胞部分將成為最大的細分市場。

由於臍帶血幹細胞易於獲取、採集過程無創且具有廣泛的治療潛力，預計在預測期內，臍帶血幹細胞細分市場將佔據最大的市場佔有率。臍帶血含有造血幹細胞，可用於治療白血病、貧血和免疫力缺乏。臍帶組織含有間質幹細胞，在整形外科和神經系統疾病方面具有潛在的應用價值。臍帶組織採集在分娩過程中安全無痛，因此被不同文化背景的人廣泛接受。私人和公共血庫正在擴大臍帶血樣本的冷凍保存和登記服務。這些能力正在鞏固該細分市場在臨床和研究應用領域的領先地位。

預計樣品分析細分市場在預測期內將實現最高的複合年成長率。

預計在預測期內，樣本分析領域將迎來最高的成長率，因為生物樣本庫和研究機構正在擴展其檢測和鑑定服務。分析項目包括活性檢測、 HLA型檢測、污染篩檢和效力測定。與人工智慧和基因組平台的整合正在推動預測建模和個人化治療方案的發展。臨床試驗和細胞療法研發管線正在推動對檢驗的高品質樣本的需求。供應商正在提供將儲存、分析和彙報相結合的配套服務。這一趨勢正在促進增值生物樣本庫服務的成長。

比最大的地區

由於北美擁有先進的醫療基礎設施、清晰的監管環境以及較高的父母意識，預計在預測期內，北美將佔據最大的市場佔有率。美國和加拿大擁有大型的公立和私立幹細胞庫，並建立了覆蓋全國的採集網路。對再生醫學和個人化治療的投資正在推動該平台的擴張。醫院和保險公司正在將幹細胞庫納入其孕產和健康計畫。領先的生物技術公司和學術研究中心的存在正在推動技術創新和標準化。

複合年成長率最高的地區：

預計亞太地區在預測期內將實現最高的複合年成長率，這主要得益於生育率、醫療保健普及率和生物銀行建設等因素的共同推動。幹細胞庫正在印度、中國、日本和韓國等國的都市區和二線城市迅速發展。政府支持的項目正在幫助意識提升、改善基礎設施並制定相關法規。當地企業正在推出價格親民的套餐和多語言諮詢服務，以覆蓋不同人群。兒童和慢性病領域對樣本分析和再生療法的需求正在成長。

免費客製化服務

訂閱本報告的用戶可從以下免費自訂選項中選擇一項：

  • 公司簡介
    • 對最多三家其他公司進行全面分析
    • 對主要企業進行SWOT分析（最多3家公司）
  • 區域分類
    • 根據客戶興趣對主要國家進行市場估算、預測和複合年成長率分析（註：基於可行性檢查）
  • 競爭基準化分析
    • 基於產品系列、地域覆蓋和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 引言

  • 概述
  • 相關利益者
  • 分析範圍
  • 分析方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 分析方法
  • 分析材料
    • 原始研究資料
    • 二手研究資訊來源
    • 先決條件

第3章 市場趨勢分析

  • 促進要素
  • 抑制因素
  • 市場機遇
  • 威脅
  • 終端用戶分析
  • 新興市場
  • 新冠疫情的感染疾病

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代產品的威脅
  • 新參與企業的威脅
  • 公司間的競爭

5. 全球幹細胞庫市場（依來源類型分類）

  • 臍帶幹細胞
  • 臍帶血
  • 臍帶組織
  • 胎盤
  • 成體幹細胞
  • 骨髓
  • 周邊血
  • 胚胎幹細胞
  • 其他來源類型

6. 全球幹細胞庫市場（依銀行類型分類）

  • 私人幹細胞庫
  • 公共幹細胞庫
  • 混合銀行

7. 全球幹細胞庫市場按服務類型分類

  • 樣本採集和運輸
  • 樣品處理
  • 樣品分析
  • 樣品儲存

8. 全球幹細胞庫市場依用途分類

  • 已使用樣品
  • 未使用的樣本

9. 全球幹細胞庫市場（依最終用戶分類）

  • 醫院和專科診所
  • 研究和學術機構
  • 製藥和生物技術公司
  • 患者及其家屬
  • 其他最終用戶

10. 全球幹細胞庫市場（按地區分類）

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章：主要趨勢

  • 合約、商業夥伴關係和合資企業
  • 企業合併（M&A）
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第12章：企業概況

  • Cord Blood Registry（CBR）
  • Cryo-Cell International
  • ViaCord
  • LifeCell International
  • StemCyte
  • China Cord Blood Corporation
  • Smart Cells International
  • CryoSave
  • BioEden
  • Cells4Life
  • Global Stem Cells Group
  • StemExpress
  • Vita 34 AG
  • ReeLabs
  • Cryoviva Biotech Pvt. Ltd.
Product Code: SMRC31829

According to Stratistics MRC, the Global Stem Cell Banking Market is accounted for $11.2 billion in 2025 and is expected to reach $22.2 billion by 2032 growing at a CAGR of 10.2% during the forecast period. Stem cell banking is the process of collecting, processing, and preserving stem cells for potential future medical use. These cells, typically derived from sources such as umbilical cord blood, bone marrow, or adipose tissue, have the unique ability to develop into various cell types and regenerate damaged tissues. The preserved stem cells can be used in regenerative medicine, transplantation, and the treatment of various diseases like leukemia, lymphoma, and immune disorders. Stored in cryogenic conditions, stem cell banking provides a valuable biological resource for individuals and families, ensuring access to personalized therapies and advanced medical treatments in the future.

According to the International Society for Stem Cell Research (ISSCR), the number of ongoing clinical trials using stem cells surpassed 7,000 globally, reflecting the rapid development of regenerative therapies and the increasing demand for quality-assured stem cell storage.

Market Dynamics:

Driver:

Rising public awareness and parental demand

Families are increasingly opting to preserve umbilical cord blood and tissue for potential future use in regenerative therapies. Educational campaigns and prenatal counseling are improving understanding of stem cell applications in genetic and immune disorders. Hospitals and birthing centers are partnering with private banks to offer collection and storage services. Demand is rising across urban and semi-urban regions with growing access to maternity care. These dynamics are propelling market expansion across preventive and personalized medicine.

Restraint:

Limited proven indications

While stem cells show promise in treating blood cancers and metabolic disorders, most applications remain experimental or restricted to clinical trials. Regulatory bodies require rigorous validation before approving new therapeutic uses. Parents may hesitate to invest in banking without clear evidence of long-term benefit. Lack of standardized protocols for emerging indications slows integration into mainstream care. These limitations continue to hinder broader adoption and reimbursement support.

Opportunity:

Increased healthcare spending and private investment

Governments are funding biobanking initiatives and public-private partnerships to support regenerative medicine. Venture capital and institutional investors are backing startups focused on cryopreservation, analytics, and cell therapy integration. Expansion of fertility clinics and maternity hospitals is creating new collection points and referral networks. Demand for long-term biological storage is rising across oncology, neurology, and rare disease segments. These trends are fostering scalable and diversified growth across the stem cell banking ecosystem.

Threat:

Data privacy, consent and ethical transparency issues

Organizations must ensure secure handling of genetic and personal data linked to stored samples. Consent protocols must be clear, age-appropriate, and legally compliant across jurisdictions. Ethical concerns around commercialization, donor rights, and future use of samples require robust governance. Regulatory scrutiny is increasing across cross-border storage and research collaborations. These risks continue to constrain platform credibility and stakeholder engagement.

Covid-19 Impact:

The pandemic disrupted maternity care and elective procedures, temporarily reducing stem cell collection volumes. However, post-pandemic recovery has emphasized preventive health and biobanking as part of long-term resilience. Hospitals resumed cord blood collection and partnered with private banks to expand access. Public interest in immune health and regenerative therapies increased during the crisis. Investment in digital consent, remote counseling, and logistics improved operational continuity. These shifts are accelerating long-term integration of stem cell banking into maternal and pediatric care.

The umbilical cord stem cells segment is expected to be the largest during the forecast period

The umbilical cord stem cells segment is expected to account for the largest market share during the forecast period due to their accessibility, non-invasive collection, and broad therapeutic potential. Cord blood contains hematopoietic stem cells used in treating leukemia, anemia, and immune deficiencies. Cord tissue offers mesenchymal stem cells with applications in orthopedic and neurological conditions. Collection is safe and painless during childbirth, making it widely acceptable across cultures. Private and public banks are scaling cryopreservation and registry services for cord-derived samples. These capabilities are boosting segment dominance across clinical and research applications.

The sample analysis segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the sample analysis segment is predicted to witness the highest growth rate as banks and research institutions expand testing and characterization services. Analysis includes viability testing, HLA typing, contamination screening, and potency assays. Integration with AI and genomic platforms is enabling predictive modeling and personalized therapy planning. Demand for validated, high-quality samples is rising across clinical trials and cell therapy pipelines. Vendors are offering bundled services that combine storage with analytics and reporting. These dynamics are accelerating growth across value-added biobanking services.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share due to its advanced healthcare infrastructure, regulatory clarity, and high parental awareness. The United States and Canada host major private and public stem cell banks with nationwide collection networks. Investment in regenerative medicine and personalized therapies is supporting platform expansion. Hospitals and insurers are integrating stem cell banking into maternity packages and wellness plans. Presence of leading biotech firms and academic research centers is driving innovation and standardization.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR as birth rates, healthcare access, and bio-banking initiatives converge. Countries like India, China, Japan, and South Korea are scaling stem cell banking across urban and tier-2 cities. Government-backed programs are supporting public awareness, infrastructure, and regulatory alignment. Local firms are launching affordable packages and multilingual counselling to reach diverse populations. Demand for sample analysis and regenerative therapies is rising across pediatric and chronic disease segments.

Key players in the market

Some of the key players in Stem Cell Banking Market include Cord Blood Registry (CBR), Cryo-Cell International, ViaCord, LifeCell International, StemCyte, China Cord Blood Corporation, Smart Cells International, CryoSave, BioEden, Cells4Life, Global Stem Cells Group, StemExpress, Vita 34 AG, ReeLabs and Cryoviva Biotech Pvt. Ltd.

Key Developments:

In July 2025, ViaCord launched its NextGen CryoPreserve(TM) platform, designed to enhance long-term viability of cord tissue stem cells. The system uses proprietary cryoprotectants and automated thawing protocols, improving therapeutic readiness for orthopedic, neurological, and autoimmune applications.

In May 2025, Cryo-Cell International partnered with Duke University's Marcus Center for Cellular Cures to advance cord blood therapies for autism and cerebral palsy. The collaboration supports FDA-regulated clinical trials and expands Cryo-Cell's therapeutic pipeline, reinforcing its leadership in translational stem cell research.

Source Types Covered:

  • Umbilical Cord Stem Cells
  • Cord Blood
  • Cord Tissue
  • Placenta
  • Adult Stem Cells
  • Bone Marrow
  • Peripheral Blood
  • Embryonic Stem Cells
  • Other Source Types

Bank Types Covered:

  • Private Stem Cell Banks
  • Public Stem Cell Banks
  • Hybrid Banks

Service Types Covered:

  • Sample Collection & Transportation
  • Sample Processing
  • Sample Analysis
  • Sample Preservation & Storage

Utilizations Covered:

  • Used Samples
  • Unused Samples

End Users Covered:

  • Hospitals & Specialty Clinics
  • Research & Academic Institutes
  • Pharmaceutical & Biotech Companies
  • Patients & Families
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Stem Cell Banking Market, By Source Type

  • 5.1 Introduction
  • 5.2 Umbilical Cord Stem Cells
  • 5.3 Cord Blood
  • 5.4 Cord Tissue
  • 5.5 Placenta
  • 5.6 Adult Stem Cells
  • 5.7 Bone Marrow
  • 5.8 Peripheral Blood
  • 5.9 Embryonic Stem Cells
  • 5.10 Other Source Types

6 Global Stem Cell Banking Market, By Bank Type

  • 6.1 Introduction
  • 6.2 Private Stem Cell Banks
  • 6.3 Public Stem Cell Banks
  • 6.4 Hybrid Banks

7 Global Stem Cell Banking Market, By Service Type

  • 7.1 Introduction
  • 7.2 Sample Collection & Transportation
  • 7.3 Sample Processing
  • 7.4 Sample Analysis
  • 7.5 Sample Preservation & Storage

8 Global Stem Cell Banking Market, By Utilization

  • 8.1 Introduction
  • 8.2 Used Samples
  • 8.3 Unused Samples

9 Global Stem Cell Banking Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals & Specialty Clinics
  • 9.3 Research & Academic Institutes
  • 9.4 Pharmaceutical & Biotech Companies
  • 9.5 Patients & Families
  • 9.6 Other End Users

10 Global Stem Cell Banking Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Cord Blood Registry (CBR)
  • 12.2 Cryo-Cell International
  • 12.3 ViaCord
  • 12.4 LifeCell International
  • 12.5 StemCyte
  • 12.6 China Cord Blood Corporation
  • 12.7 Smart Cells International
  • 12.8 CryoSave
  • 12.9 BioEden
  • 12.10 Cells4Life
  • 12.11 Global Stem Cells Group
  • 12.12 StemExpress
  • 12.13 Vita 34 AG
  • 12.14 ReeLabs
  • 12.15 Cryoviva Biotech Pvt. Ltd.

List of Tables

  • Table 1 Global Stem Cell Banking Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Stem Cell Banking Market Outlook, By Source Type (2024-2032) ($MN)
  • Table 3 Global Stem Cell Banking Market Outlook, By Umbilical Cord Stem Cells (2024-2032) ($MN)
  • Table 4 Global Stem Cell Banking Market Outlook, By Cord Blood (2024-2032) ($MN)
  • Table 5 Global Stem Cell Banking Market Outlook, By Cord Tissue (2024-2032) ($MN)
  • Table 6 Global Stem Cell Banking Market Outlook, By Placenta (2024-2032) ($MN)
  • Table 7 Global Stem Cell Banking Market Outlook, By Adult Stem Cells (2024-2032) ($MN)
  • Table 8 Global Stem Cell Banking Market Outlook, By Bone Marrow (2024-2032) ($MN)
  • Table 9 Global Stem Cell Banking Market Outlook, By Peripheral Blood (2024-2032) ($MN)
  • Table 10 Global Stem Cell Banking Market Outlook, By Embryonic Stem Cells (2024-2032) ($MN)
  • Table 11 Global Stem Cell Banking Market Outlook, By Other Source Types (2024-2032) ($MN)
  • Table 12 Global Stem Cell Banking Market Outlook, By Bank Type (2024-2032) ($MN)
  • Table 13 Global Stem Cell Banking Market Outlook, By Private Stem Cell Banks (2024-2032) ($MN)
  • Table 14 Global Stem Cell Banking Market Outlook, By Public Stem Cell Banks (2024-2032) ($MN)
  • Table 15 Global Stem Cell Banking Market Outlook, By Hybrid Banks (2024-2032) ($MN)
  • Table 16 Global Stem Cell Banking Market Outlook, By Service Type (2024-2032) ($MN)
  • Table 17 Global Stem Cell Banking Market Outlook, By Sample Collection & Transportation (2024-2032) ($MN)
  • Table 18 Global Stem Cell Banking Market Outlook, By Sample Processing (2024-2032) ($MN)
  • Table 19 Global Stem Cell Banking Market Outlook, By Sample Analysis (2024-2032) ($MN)
  • Table 20 Global Stem Cell Banking Market Outlook, By Sample Preservation & Storage (2024-2032) ($MN)
  • Table 21 Global Stem Cell Banking Market Outlook, By Utilization (2024-2032) ($MN)
  • Table 22 Global Stem Cell Banking Market Outlook, By Used Samples (2024-2032) ($MN)
  • Table 23 Global Stem Cell Banking Market Outlook, By Unused Samples (2024-2032) ($MN)
  • Table 24 Global Stem Cell Banking Market Outlook, By End User (2024-2032) ($MN)
  • Table 25 Global Stem Cell Banking Market Outlook, By Hospitals & Specialty Clinics (2024-2032) ($MN)
  • Table 26 Global Stem Cell Banking Market Outlook, By Research & Academic Institutes (2024-2032) ($MN)
  • Table 27 Global Stem Cell Banking Market Outlook, By Pharmaceutical & Biotech Companies (2024-2032) ($MN)
  • Table 28 Global Stem Cell Banking Market Outlook, By Patients & Families (2024-2032) ($MN)
  • Table 29 Global Stem Cell Banking Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.